BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (NYSE MKT: TXMD), an innovative women’s healthcare company, today announced the schedule of nine posters and oral presentations at upcoming medical conferences related to Yuvvexy, the conditionally-approved trade name for TX-004HR, an investigational applicator-free vaginal estradiol softgel capsule in development for the treatment of moderate-to-severe vaginal pain during sexual intercourse (dyspareunia), a symptom of vulvar and vaginal atrophy (VVA), due to menopause.
The presentations support the results from the Yuvvexy clinical development program and further identify women’s perceptions of VVA and current available treatment options. Additional data to be presented provide new insights about the lack of understanding of VVA as a serious medical condition. The posters and presentations will be made at annual meetings of the International Menopause Society (IMS) on September 28 - October 1 in Prague, Czech Republic, and the North American Menopause Society (NAMS) on October 5-8 in Orlando, Florida.
“These presentations reflect the breadth and depth of our Yuvvexy clinical program, including the previously-presented phase 3 Rejoice Trial data, as well as the need for improved understanding of VVA as a serious medical condition, its symptoms such as dyspareunia, and the available treatment options,” said TherapeuticsMD co-founder and Chief Clinical Officer Brian Bernick, M.D. “We look forward to our IMS and NAMS presentations regarding Yuvvexy and, if approved, establishing this innovative product as a highly differentiated new therapy designed to satisfy the unmet needs of menopausal women suffering from symptoms of VVA.”
Last updated on: 23/09/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.